Back to Search Start Over

Risk and benefit of neoadjuvant therapy among patients undergoing resection for non-small-cell lung cancer

Authors :
Chukwumere Nwogu
Anthony Picone
Sai Yendamuri
Elisabeth U. Dexter
Todd L. Demmy
Adrienne Groman
Austin Miller
Grace K. Dy
Mark Hennon
Source :
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 53(3)
Publication Year :
2017

Abstract

OBJECTIVES: Neoadjuvant therapy has emerged as a favoured treatment paradigm for patients with clinical N2 disease undergoing surgical resection for non-small-cell lung cancer. It is unclear whether such a treatment paradigm affects perioperative outcomes. We sought to examine the National Cancer Database (NCDB) to assess the impact of neoadjuvant therapy on perioperative outcomes and long-term survival in these patients. METHODS: All patients with a history of non-small-cell lung cancer undergoing anatomical resection between 2004 and 2014 were included. Thirty-day and 90-day mortality of all patients having neoadjuvant therapy versus those who did not were compared. In addition, the impact of neoadjuvant therapy on the overall survival of patients with clinical N2 disease was examined. RESULTS: Of the 134 428 selected patients, 9896 (7.4%) patients had neoadjuvant chemotherapy. Patients undergoing neoadjuvant therapy had a higher 30-day (3% vs 2.6%; P

Details

ISSN :
1873734X
Volume :
53
Issue :
3
Database :
OpenAIRE
Journal :
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
Accession number :
edsair.doi.dedup.....a431c963b8f19966c9b75081b1f6da09